Haemonetics Corporation (HAE) Shares Bought by Stifel Financial Corp

Stifel Financial Corp lifted its holdings in Haemonetics Corporation (NYSE:HAE) by 28.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 11,924 shares of the medical instruments supplier’s stock after purchasing an additional 2,675 shares during the quarter. Stifel Financial Corp’s holdings in Haemonetics Corporation were worth $470,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Arizona State Retirement System grew its position in shares of Haemonetics Corporation by 1.1% in the 2nd quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 300 shares during the period. Gotham Asset Management LLC acquired a new position in shares of Haemonetics Corporation in the 1st quarter valued at approximately $641,000. BlackRock Inc. grew its position in shares of Haemonetics Corporation by 48,854.9% in the 1st quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock valued at $255,175,000 after purchasing an additional 6,276,880 shares during the period. Aperio Group LLC grew its position in shares of Haemonetics Corporation by 15.0% in the 2nd quarter. Aperio Group LLC now owns 10,695 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 1,393 shares during the period. Finally, OppenheimerFunds Inc. grew its position in shares of Haemonetics Corporation by 27.9% in the 1st quarter. OppenheimerFunds Inc. now owns 18,047 shares of the medical instruments supplier’s stock valued at $732,000 after purchasing an additional 3,934 shares during the period.

Several brokerages recently issued reports on HAE. Zacks Investment Research lowered Haemonetics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. JMP Securities upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research report on Thursday, July 13th. BidaskClub upgraded Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 price objective on shares of Haemonetics Corporation in a research report on Thursday, July 27th. Finally, TheStreet upgraded Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. Haemonetics Corporation currently has an average rating of “Hold” and an average price target of $45.83.

Shares of Haemonetics Corporation (NYSE:HAE) opened at 47.56 on Wednesday. The firm has a 50-day moving average price of $44.86 and a 200 day moving average price of $42.12. The company has a market cap of $2.50 billion, a PE ratio of 617.66 and a beta of 0.87. Haemonetics Corporation has a 1-year low of $33.01 and a 1-year high of $47.96.

Haemonetics Corporation (NYSE:HAE) last announced its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The firm had revenue of $211.00 million during the quarter, compared to analysts’ expectations of $211.29 million. During the same quarter last year, the firm posted $0.25 earnings per share. The company’s revenue for the quarter was up .5% compared to the same quarter last year. On average, equities analysts anticipate that Haemonetics Corporation will post $1.61 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/11/01/haemonetics-corporation-hae-shares-bought-by-stifel-financial-corp.html.

Haemonetics Corporation Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

What are top analysts saying about Haemonetics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Haemonetics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit